Neonatal And Congenital Anomaly Neurosurgery Program Research and Innovation

LIke ThisLIke ThisLIke ThisLIke ThisLIke This

Contact the Neonatal and Congenital Anomaly Neurosurgery Program

  • 617-355-6008

Our pioneering research

Dr. Warf and his Boston Children's Hospital colleagues have identified that Endoscopic Third Ventriculostomy/Choroid Plexus Cauterization (ETV/CPC) prevents shunt dependence in many children, including those with no urgent access to subspecialty care for shunt malfunction - particularly in resource-limited environments.

Our research is now translating to optimal treatment selection and outcomes for children with hydrocephalus worldwide.

Dr. Warf is currently involved in the following clinical trials:

Innovative treatment for infants with hydrocephalus: ETV/CPC

Boston Children's Neonatal and Congenital Anomaly Neurosurgery Program Director Benjamin Warf, MD, developed a novel surgical technique for treating hydrocephalus in infants, combining endoscopic third ventriculostomy with bilateral choroid plexus cauterization (ETV/CPC).

ETV/CPC involves the use of an endoscope to create an opening in the floor of the third ventricle and combined with endoscopic cauterization of the choroid plexus (CP) at the time of the ETV.

Cauterization of the CP tissue in the lateral ventricles of the brain has been demonstrated to decrease cerebrospinal fluid (CSF) production. This combined procedure addresses both production and absorption issues to return the flow of CSF in the brain to a normal state. The combined procedure is shown to be a more effective treatment in infants then ETV alone.

Learn more about ETV/CPC.

The future of pediatrics will be forged by thinking differently, breaking paradigms and joining together in a shared vision of tackling the toughest challenges before us.”
- Sandra L. Fenwick, President and CEO

Boston Children's Hospital 300 Longwood Avenue, Boston, MA 02115 617-355-6000 | 800-355-7944

Close